Stiefel acquires WBI anti-inflammatory agent development, commercialization rights
The acquisition follows the previously announced asset purchase agreement. WBI-1001 is a non-steroidal, topical anti-inflammatory new chemical entity (NCE) agent, which has demonstrated efficacy and safety in Ph1
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.